Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma

References

• 1 Schlageter M, Terracciano LM, D'Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J. Gastroenterol. 20(43), 15955–15964 (2014).
  MedlineGoogle Scholar
• 2 Cabibbo G, Maida M, Genco C, Antonucci M, Camma C. Causes of and prevention strategies for hepatocellular carcinoma. Semin. Oncol. 39(4), 374–383 (2012).
  MedlineGoogle Scholar
• 3 Choiniere J, Wang L. Exposure to inorganic arsenic can lead to gut microbe perturbations and hepatocellular carcinoma. Acta Pharm. Sin. B 6(5), 426–429 (2016).
  MedlineGoogle Scholar
• 4 Stepien M, Hughes DJ, Hybsier S et al. Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. Br. J. Cancer 116(5), 688–696 (2017).
  Medline CASGoogle Scholar
• 5 Ma X, Yang Y, Li HL et al. Dietary trace element intake and liver cancer risk: results from two population-based cohorts in China. Int. J. Cancer 140(5), 1050–1059 (2017).
  Medline CASGoogle Scholar
• 6 Garcia-Esquinas E, Pollan M, Tellez-Plaza M et al. Cadmium exposure and cancer mortality in a prospective cohort: the strong heart study. Environ. Health Perspect. 122(4), 363–370 (2014).
  Medline CASGoogle Scholar
• 7 Rinaldi M, Micali A, Marini H et al. Cadmium, organ toxicity and therapeutic approaches. A review on brain, kidney and testis damage. Curr. Med. Chem. 24(35), 3879–3893 (2017).
  Medline CASGoogle Scholar
• 8 Ledda C, Loreto C, Zammit C et al. Noninfective occupational risk factors for hepatocellular carcinoma: a review (review). Mol. Med. Rep. 15(2), 511–533 (2017).
  Medline CASGoogle Scholar
• 9 Zhang L, Huang Y, Zhu Y, Yu Z, Shao M, Luo Y. Identification and characterization of cadmium-related genes in liver carcinoma. Biol. Trace Elem. Res. 182(2), 238–247 (2017).
  MedlineGoogle Scholar
• 10 Stelzer G, Rosen N, Plaschkes I et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinformatics 54, 1.30.1–1.30.33 (2016).
  MedlineGoogle Scholar
• 11 Mo Z, Zheng S, Lv Z et al. Senescence marker protein 30 (SMP30) serves as a potential prognostic indicator in hepatocellular carcinoma. Sci. Rep. 6, 39376 (2016).
  Medline CASGoogle Scholar
• 12 Zhang RR, Pointer KB, Kuo JS. Excitotoxic SLC7A11 expression is a marker of poor glioblastoma survival and a potential therapeutic target. Neurosurgery 77(6), N16–N17 (2015).
  MedlineGoogle Scholar
• 13 Wu Y, Sun X, Song B, Qiu X, Zhao J. MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. Cancer Med. 6(7), 1686–1697 (2017).
  Medline CASGoogle Scholar
• 14 Toyoda M, Kaira K, Ohshima Y et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br. J. Cancer 110(10), 2506–2513 (2014).
  Medline CASGoogle Scholar
• 15 Kinoshita H, Okabe H, Beppu T et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma. Oncol. Rep. 29(2), 685–689 (2013).
  Medline CASGoogle Scholar
• 16 Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. Increased expression of system xc- in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol. Cancer Res. 14(12), 1229–1242 (2016).
  Medline CASGoogle Scholar
• 17 Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev. 26(17), 1236–1246 (2017).
  Medline CASGoogle Scholar
• 18 Drayton RM, Dudziec E, Peter S et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin. Cancer Res. 20(7), 1990–2000 (2014).
  Medline CASGoogle Scholar
• 19 Ma MZ, Chen G, Wang P et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett. 368(1), 88–96 (2015).
  Medline CASGoogle Scholar
• 20 Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381(1), 96–103 (2016).
  Medline CASGoogle Scholar
• 21 Sleire L, Skeie BS, Netland IA et al. Drug repurposing: sulfasalazine sensitizes gliomas to Gamma Knife radiosurgery by blocking cystine uptake through system xc-, leading to glutathione depletion. Oncogene 34(49), 5951–5959 (2015).
  Medline CASGoogle Scholar
• 22 Xie Y, Hou W, Song X et al. Ferroptosis: process and function. Cell Death Differ. 23(3), 369–379 (2016).
  Medline CASGoogle Scholar
• 23 Jiang L, Kon N, Li T et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520(7545), 57–62 (2015).
  Medline CASGoogle Scholar
• 24 Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front. Cell Dev. Biol. 5, 18 (2017).
  MedlineGoogle Scholar
• 25 Wada T, Ishimoto T, Seishima R et al. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 104(10), 1323–1329 (2013).
  Medline CASGoogle Scholar
• 26 Peng F, Li H, You Q et al. CD147 as a novel prognostic biomarker for hepatocellular carcinoma: a meta-analysis. Biomed. Res. Int. 2017, 5019367 (2017).
  Google Scholar
• 27 Grass GD, Dai L, Qin Z, Parsons C, Toole BP. CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance. Adv. Cancer Res. 123, 351–373 (2014).
  Medline CASGoogle Scholar
• 28 Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65(16), 7446–7454 (2005).
  Medline CASGoogle Scholar
• 29 Guo W, Zhao Y, Zhang Z et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 312(1), 55–61 (2011).
  Medline CASGoogle Scholar